林聪湄;张浩;卢鑫可;齐璐璐;申屠旭萍;冯华朋;邬丽;

• 1:中国计量大学量新学院
• 2:中国计量大学生命科学学院
• 3:浙江理工大学生命科学与医药学院

摘要(Abstract)：

新型冠状病毒（SARS-CoV-2）是一种新发高传染性的冠状病毒。因其编码有限的病毒蛋白，SARS-CoV-2需要借助多种宿主因子完成其生命周期，而大多数参与其中的宿主因子及作用机理仍不明确。因此，研究参与SARS-CoV-2复制周期的宿主因子及作用机理，将有助于我们对病毒生命周期的认识及寻找抗SARS-CoV-2药物的作用靶点，从而可以帮助人们更加有效地防控新冠疫情。本文归纳了参与SARS-CoV-2复制周期中入侵的宿主因子，对全面理解SARS-CoV-2致病的分子机制、病毒感染的快速诊断及抗病毒新药研发具有重要的意义。

关键词(KeyWords)： 新型冠状病毒;宿主因子;生命周期;入侵

Abstract:

Keywords:

基金项目(Foundation): 浙江省大学生科技创新活动计划资助项目(项目号：2021R409024)，题目：过表达ACE2并利用CRISPR/Cas9技术敲除IFITM3基因的疫苗高产细胞株的构建;; 国家级大学生创新创业训练计划资助项目(项目号：202010356046)，题目：双表达人新型冠状病毒受体蛋白ACE2和TMPRSS2的Vero E6疫苗高产细胞株的构建;; 浙江省自然科学基金(项目号：LQ22C180003)题目：宿主因子S100A4与流感病毒M2互作调控流感病毒复制的分子机制研究~~

作者(Authors): 林聪湄;张浩;卢鑫可;齐璐璐;申屠旭萍;冯华朋;邬丽;

DOI: 10.13242/j.cnki.bingduxuebao.210247

参考文献(References)：

• [1] WHO. COVID-19 weekly epidemiological update[J/OL]. https：//www. who. int/emergencies/diseases/novel-coronavirus-2019/situation-reports.
• [2] Zhang H,Penninger J M,Li Y,Zhong N,Slutsky A S.Angiotensin-converting enzyme 2(ACE2)as a SARSCoV-2 receptor:molecular mechanisms and potential therapeutic target[J]. Intensive Care Med,2020,46(4):586-590.
• [3] Wu A,Peng Y,Huang B,Ding X,Wang X,Niu P,Meng J,Zhu Z,Zhang Z,Wang J,Sheng J,Quan L,Xia Z, Tan W, Cheng G, Jiang T. Genome composition and divergence of the novel coronavirus(2019-nCoV)originating in China[J]. Cell Host Microbe,2020,27(3):325-328.
• [4] Wang M Y,Zhao R,Gao L J,Gao X F,Wang D P,Cao J M. SARS-CoV-2:structure, biology, and structure-based therapeutics development[J]. Front Cell Infect Microbiol,2020,10:587269.
• [5] Lv L,Zhang L. Host proviral and antiviral factors for SARS-CoV-2[J/OL]. Virus Genes,2021,57(6):4 75-488. DOI:10.1007/s11262-021-01869-2.
• [6] Chen Y, Liu Q, Guo D. Emerging coronaviruses:genome structure, replication, and pathogenesis[J/OL]. J Med Virol,2020,92(4):418-423. DOI:10.1002/jmv.25681.
• [7] Wang Q,Zhang Y,Wu L,Niu S,Song C,Zhang Z,Lu G,Qiao C,Hu Y,Yuen K Y,Wang Q,Zhou H,Yan J,Qi J. Structural and functional basis of SARSCoV-2 entry by using human ACE2[J/OL]. Cell,2020, 181(4):894-904 e9. DOI:10.1016/j.cell.2020.03.045.
• [8] Tikellis C, Thomas M C. Angiotensin-converting enzyme 2(ACE2)is a key modulator of the renin angiotensin system in health and disease[J/OL]. Int J Pept, 2012, 2012:256294. DOI:10.1155/2012/256294.
• [9] Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics[J]. Drug Dev Res,2020,81(5):537-540.
• [10]Hu Y,Meng X,Zhang F,Xiang Y,Wang J. The in vitro antiviral activity of lactoferrin against common human coronaviruses and SARS-CoV-2 is mediated by targeting the heparan sulfate co-receptor[J/OL]. Emerg Microbes Infect,2021,10(1):317-330. DOI:10.1080/22221751.2021.1888660.
• [11]Clausen T M,Sandoval D R,Spliid C B,Pihl J,Perrett H R,Painter C D,Narayanan A,Majowicz S A,Kwong E M,McVicar R N,Thacker B E,Glass C A,Yang Z,Torres J L,Golden G J,Bartels P L,Porell R N,Garretson A F,Laubach L,Feldman J,Yin X,Pu Y,Hauser B M,Caradonna T M,Kellman B P,Martino C,Gordts P,Chanda S K,Schmidt A G,Godula K,Leibel S L,Jose J,Corbett K D,Ward A B,Carlin A F,Esko J D. SARS-CoV-2 infection depends on cellular heparan sulfate and ACE2[J/OL].Cell,2020,183(4):1043-1057 e15. DOI:10.1016/j.cell.2020.09.033.
• [12]Salah H M,Mehta J L. Heparan sulfate consumption as a potential mechanism of intra-cardiac thrombosis in SARS-CoV-2 infection[J]. Heart Lung,2021,50(2):242-243.
• [13]Kim C H. SARS-CoV-2 evolutionary adaptation toward host entry and recognition of receptor o-acetyl sialylation in virus-host interaction[J/OL]. Int J Mol Sci,2020,21(12):4549. DOI:10.3390/ijms21124549.
• [14]Chu H,Hu B,Huang X,Chai Y,Zhou D,Wang Y,Shuai H,Yang D,Hou Y,Zhang X,Yuen T T,Cai J P,Zhang A J,Zhou J,Yuan S,To K K,Chan I H,Sit K Y,Foo D C,Wong I Y,Ng A T,Cheung T T,Law S Y,Au W K,Brindley M A,Chen Z,Kok K H,Chan J F,Yuen K Y. Host and viral determinants for efficient SARS-CoV-2 infection of the human lung[J].Nat Commun,2021,12(1):134.
• [15]Daly J L,Simonetti B,Klein K,Chen K E,Williamson M K,Antón-Plágaro C,Shoemark D K,Simón-Gracia L,Bauer M,Hollandi R,Greber U F,Horvath P,Sessions R B,Helenius A,Hiscox J A,Teesalu T,Matthews D A,Davidson A D,Collins B M,Cullen P J,Yamauchi Y. Neuropilin-1 is a host factor for SARSCoV-2 infection[J]. Science,2020,370(6518):861-865.
• [16]Cantuti-Castelvetri L,Ojha R,Pedro L D,Djannatian M,Franz J,Kuivanen S,van der Meer F,Kallio K,Kaya T, Anastasina M, Smura T, Levanov L,Szirovicza L,Tobi A,Kallio-Kokko H,Osterlund P,Joensuu M,Meunier F A,Butcher S J,Winkler M S,Mollenhauer B,Helenius A,Gokce O,Teesalu T,Hepojoki J,Vapalahti O,Stadelmann C,Balistreri G,Simons M. Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity[J]. Science,2020,370(6518):856-860.
• [17]Perez-Miller S,Patek M,Moutal A,Duran P,Cabel C R, Thorne C A, Campos S K, Khanna R. Novel compounds targeting neuropilin receptor 1 with potential to interfere with SARS-CoV-2 virus entry[J/OL]. ACS Chem Neurosci, 2021, 12(8):1299-1312. DOI:10.1021/acschemneuro.0c00619.
• [18]Wei C,Wan L,Yan Q,Wang X,Zhang J,Yang X,Zhang Y,Fan C,Li D,Deng Y,Sun J,Gong J,Yang X,Wang Y,Wang X,Li J,Yang H,Li H,Zhang Z,Wang R,Du P,Zong Y,Yin F,Zhang W,Wang N,Peng Y,Lin H,Feng J,Qin C,Chen W,Gao Q,Zhang R,Cao Y,Zhong H. HDL-scavenger receptor B type 1 facilitates SARS-CoV-2 entry[J]. Nat Metab,2020,2(12):1391-1400.
• [19]Wei J,Alfajaro M M,DeWeirdt P,Hanna R,LuCulligan W,Cai W,Strine M,Zhang S-M,Graziano V, Schmitz C, Chen J, Mankowski M, Filler R,Ravindra N,Gasque V,Miguel F,Patil A,Chen H,Oguntuyo K,Wilen C. Genome-wide CRISPR screens reveal host factors critical for SARS-CoV-2 infection[J/OL]. Cell,2021,184(1):76-91. DOI:10.1016/j.cell.2020.10.028.
• [20]Andersson U,Ottestad W,Tracey K J. Extracellular HMGB1:a therapeutic target in severe pulmonary inflammation including COVID-19?[J/OL]. Mol Med,2020,26(1):42. DOI:10.1186/s10020-020-00172-4.
• [21]Gautret P,Lagier J C,Parola P,Hoang V T,Meddeb L,Mailhe M,Doudier B,Courjon J,Giordanengo V,Vieira V E,Tissot Dupont H,HonoréS,Colson P,Chabrière E,La Scola B,Rolain J M,Brouqui P,Raoult D. Hydroxychloroquine and azithromycin as a treatment of COVID-19:results of an open-label nonrandomized clinical trial[J]. Int J Antimicrob Agents,2020,56(1):105949.
• [22]Yan R,Zhang Y,Li Y,Xia L,Guo Y,Zhou Q.Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2[J/OL]. Science,2020,367(6485):1444-1448. DOI:10.1126/science.abb2762.
• [23]Scalise M,Indiveri C. Repurposing nimesulide,a potent inhibitor of the B0AT1 subunit of the SARS-CoV-2receptor,as a therapeutic adjuvant of COVID-19[J/OL]. SLAS Discov,2020,25(10):1171-1173. DOI:10.1177/2472555220934421.
• [24]Wang S,Qiu Z,Hou Y,Deng X,Xu W,Zheng T,Wu P,Xie S,Bian W,Zhang C,Sun Z,Liu K,Shan C,Lin A,Jiang S,Xie Y,Zhou Q,Lu L,Huang J,Li X. AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cells[J]. Cell Res,2021,31(2):126-140.
• [25]Chi X,Yan R,Zhang J,Zhang G,Zhang Y,Hao M,Zhang Z,Fan P,Dong Y,Yang Y,Chen Z,Guo Y,Zhang J,Li Y,Song X,Chen Y,Xia L,Fu L,Hou L,Xu J,Yu C,Li J,Zhou Q,Chen W. A neutralizing human antibody binds to the N-terminal domain of the spike protein of SARS-CoV-2[J/OL]. Science,2020,369(6504):650-655. DOI:10.1126/science.abc6952.
• [26]Bouhaddou M, Memon D, Meyer B, White K M,Rezelj V V,Correa Marrero M,Polacco B J,Melnyk J E,Ulferts S,Kaake R M,Batra J,Richards A L,Stevenson E, Gordon D E, Rojc A, Obernier K,Fabius J M,Soucheray M,Miorin L,Moreno E,Koh C,Tran Q D,Hardy A,Robinot R,Vallet T,NilssonPayant B E, Hernandez-Armenta C, Dunham A,Weigang S,Knerr J,Modak M,Quintero D,Zhou Y,Dugourd A,Valdeolivas A,Patil T,Li Q,Huttenhain R, Cakir M, Muralidharan M, Kim M, Jang G,Tutuncuoglu B,Hiatt J,Guo J Z,Xu J,Bouhaddou S,Mathy C J P,Gaulton A,Manners E J,Felix E,Shi Y,Goff M,Lim J K,McBride T,O'Neal M C,Cai Y,Chang J C J,Broadhurst D J,Klippsten S,De Wit E,Leach A R,Kortemme T,Shoichet B,Ott M,Saez-Rodriguez J,tenOever B R,Mullins R D,Fischer E R,Kochs G,Grosse R,Garcia-Sastre A,Vignuzzi M,Johnson J R,Shokat K M,Swaney D L,Beltrao P,Krogan N J. The global phosphorylation landscape of SARS-CoV-2 infection[J/OL]. Cell,2020,182(3):685-712 e19.
• [27]Wang K,Chen W,Zhang Z,Deng Y,Lian J Q,Du P,Wei D,Zhang Y,Sun X X,Gong L,Yang X,He L,Zhang L,Yang Z,Geng J J,Chen R,Zhang H,Wang B,Zhu Y M,Nan G,Jiang J L,Li L,Wu J,Lin P,Huang W,Xie L,Zheng Z H,Zhang K,Miao J L,Cui H Y,Huang M,Zhang J,Fu L,Yang X M,Zhao Z,Sun S,Gu H,Wang Z,Wang C F,Lu Y,Liu Y Y,Wang Q Y,Bian H,Zhu P,Chen Z N. CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells[J/OL]. Signal Transduct Target Ther,2020,5(1):8. DOI:10.1038/s41392-020-0110-5.
• [28]Ragotte R J,Pulido D,Donnellan F R,Hill M L,Gorini G,Davies H,Brun J,McHugh K,King L D W,Skinner K,Miura K,Long C A,Zitzmann N,Draper S J. Human basigin(CD147)does not directly interact with SARS-CoV-2 spike glycoprotein[J/OL].mSphere,2021,6(4):e0064721.
• [29]Crosnier C,Bustamante L Y,Bartholdson S J,Bei A K, Theron M, Uchikawa M, Mboup S, Ndir O,Kwiatkowski D P, Duraisingh M T, Rayner J C,Wright G J. Basigin is a receptor essential for erythrocyte invasion by plasmodium falciparum[J]. Nature,2011,480(7378):534-537.
• [30]Ulrich H,Pillat M M. CD147 as a target for COVID-19treatment:suggested effects of azithromycin and stem cell engagement[J/OL]. Stem Cell Rev Rep,2020,16(3):434-440. DOI:10.1007/s12015-020-09976-7.
• [31]Ibrahim I M,Abdelmalek D H,Elshahat M E,Elfiky A A. COVID-19 spike-host cell receptor GRP78 binding site prediction[J/OL]. J Infect,2020,80(5):554-562.DOI:10.1016/j.jinf.2020.02.026.
• [32]Sabirli R,Koseler A,Goren T,Turkcuer I,Kurt O.High GRP78 levels in COVID-19 infection:a casecontrol study[J/OL]. Life Sci,2021,265:118781.DOI:10.1016/j.lfs.2020.118781.
• [33]Puzyrenko A,Jacobs E R,Sun Y,Felix J C,Sheinin Y,Ge L,Lai S,Dai Q,Gantner B N,Nanchal R,North P E, Simpson P M, Rui H, Benjamin I J.Pneumocytes are distinguished by highly elevated expression of the ER stress biomarker GRP78,a coreceptor for SARS-CoV-2,in COVID-19 autopsies[J/OL]. Cell Stress Chaperones,2021,26(5):859-868.DOI:10.1007/s12192-021-01230-4.
• [34]Balmeh N, Mahmoudi S, Mohammadi N,Karabedianhajiabadi A. Predicted therapeutic targets for COVID-19 disease by inhibiting SARS-CoV-2 and its related receptors[J/OL]. Inform Med Unlocked,2020,20:100407. DOI:https：//doi. org/10.1016/j.imu.2020.100407.
• [35]Gu Y,Cao J,Zhang X,Gao H,Wang Y,Wang J,Zhang J,Shen G,Jiang X,Yang J,Zheng X,Xu J,Zhang C,Lan F,Di Q,Zhao Y,Xu G,Xie Y,Luo M,Lu Z. Interaction network of SARS-CoV-2 with host receptome through spike protein[J/OL]. BioRxiv,2020.DOI:https：//doi.org/10.1101/2020.09.09.287508.
• [36]Collins D P,Steer C J. Binding of the SARS-CoV-2spike protein to the asialoglycoprotein receptor on human primary hepatocytes and immortalized hepatocyte-like cells by confocal analysis[J/OL]. Hepat Med,2021,13:37-44. DOI:10.2147/HMER.S301979.
• [37]Puelles V G,Lutgehetmann M,Lindenmeyer M T,Sperhake J P, Wong M N, Allweiss L, Chilla S,Heinemann A,Wanner N,Liu S,Braun F,Lu S,Pfefferle S,Schroder A S,Edler C,Gross O,Glatzel M,Wichmann D,Wiech T,Kluge S,Pueschel K,Aepfelbacher M, Huber T B. Multiorgan and renal tropism of SARS-CoV-2[J/OL]. N Engl J Med,2020,383(6):590-592. DOI:10.1056/NEJMc2011400.
• [38]Hasan A,Paray B A,Hussain A,Qadir F A,Attar F,Aziz F M,Sharifi M,Derakhshankhah H,Rasti B,Mehrabi M,Shahpasand K,Saboury A A,Falahati M.A review on the cleavage priming of the spike protein on coronavirus by angiotensin-converting enzyme-2 and furin[J/OL]. J Biomol Struct Dyn,2021,39(8):3025-3033. DOI:10.1080/07391102.2020.1754293.
• [39]Shang J,Wan Y,Luo C,Ye G,Geng Q,Auerbach A,Li F. Cell entry mechanisms of SARS-CoV-2[J/OL]. Proc Natl Acad Sci U S A,2020,117(21):11727-11734. DOI:10.1073/pnas.2003138117.
• [40]Fitzgerald K. Furin protease:from SARS-CoV-2 to anthrax,diabetes,and hypertension[J/OL]. Perm J,2020,24. DOI:10.7812/TPP/20.187.
• [41]Palit P,Chattopadhyay D,Thomas S,Kundu A,Kim H S,Rezaei N. Phytopharmaceuticals mediated furin and TMPRSS2 receptor blocking:can it be a potential therapeutic option for COVID-19?[J/OL].Phytomedicine, 2021, 85:153396. DOI:10.1016/j.phymed.2020.153396.
• [42]Hoffmann M,Kleine-Weber H,Schroeder S,Kruger N,Herrler T,Erichsen S,Schiergens T S,Herrler G,Wu N H, Nitsche A, Muller M A, Drosten C,Pohlmann S. SARS-CoV-2 cell entry depends on ACE2and TMPRSS2 and is blocked by a clinically proven protease inhibitor[J/OL]. Cell,2020,181(2):271-280e8. DOI:10.1016/j.cell.2020.02.052.
• [43]Bestle D,Heindl M R,Limburg H,Van Lam van T,Pilgram O, Moulton H, Stein D A, Hardes K,Eickmann M,Dolnik O,Rohde C,Klenk H D,Garten W, Steinmetzer T, B?ttcher-Friebertsh?user E.TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells[J/OL]. Life Sci Alliance,2020,3(9):e202000786. DOI:10.26508/lsa.202000786.
• [44]Thunders M, Delahunt B. Gene of the month:TMPRSS2(transmembrane serine protease 2)[J]. J Clin Pathol,2020,73(12):773-776.
• [45]Gomes C P,Fernandes D E,Casimiro F,da Mata G F,Passos M T,Varela P,Mastroianni-Kirsztajn G,Pesquero J B. Cathepsin L in COVID-19:from pharmacological evidences to genetics[J/OL]. Front Cell Infect Microbiol, 2020, 10:589505. DOI:10.1136/jclinpath-2020-206987.
• [46]Smieszek S P,Przychodzen B P,Polymeropoulos M H.Amantadine disrupts lysosomal gene expression:a hypothesis for COVID-19 treatment[J]. Int J Antimicrob Agents,2020,55(6):106004.
• [47]Faheem, Kumar B K, Sekhar K, Kunjiappan S,Jamalis J, Bala?a-Fouce R, Tekwani B L,Sankaranarayanan M. Druggable targets of SARS-CoV-2 and treatment opportunities for COVID-19[J/OL].Bioorg Chem,2020,104:104269. DOI:10.1016/j.bioorg.2020.104269.
• [48]Liu T,Luo S,Libby P,Shi G P. Cathepsin L-selective inhibitors:a potentially promising treatment for COVID-19 patients[J/OL]. Pharmacol Ther, 2020, 213:107587. DOI:10.1016/j.pharmthera.2020.107587.
• [49]Black R A,Rauch C T,Kozlosky C J,Peschon J J,Slack J L,Wolfson M F,Castner B J,Stocking K L,Reddy P,Srinivasan S,Nelson N,Boiani N,Schooley K A,Gerhart M,Davis R,Fitzner J N,Johnson R S,Paxton R J, March C J, Cerretti D P. A metalloproteinase disintegrin that releases tumournecrosis factor-alpha from cells[J/OL]. Nature,1997,385(6618):729-733. DOI:10.1038/385729a0.
• [50]Patel V B,Clarke N,Wang Z,Fan D,Parajuli N,Basu R,Putko B,Kassiri Z,Turner A J,Oudit G Y.Angiotensin II induced proteolytic cleavage of myocardial ACE2 is mediated by TACE/ADAM-17:a positive feedback mechanism in the RAS[J]. J Mol Cell Cardiol,2014,66:167-176.
• [51]Gheblawi M,Wang K,Viveiros A,Nguyen Q,Zhong J C,Turner A J,Raizada M K,Grant M B,Oudit G Y. Angiotensin-converting enzyme 2:SARS-CoV-2Receptor and Regulator of the renin-angiotensin system:celebrating the 20th anniversary of the discovery of ACE2[J/OL]. Circ Res,2020,126(10):1456-1474.DOI:10.1161/CIRCRESAHA.120.317015.
• [52]Palau V,Riera M,Soler M J. ADAM17 inhibition may exert a protective effect on COVID-19[J/OL]. Nephrol Dial Transplant, 2020, 35(6):1071-1072. DOI:10.1093/ndt/gfaa093.
• [53]冯晔囡，宋洋，王世文，陈操，许文波.全球新型冠状病毒变异株研究进展[J/OL].病毒学报，2021,37(03):695-711. DOI:10.13242/j. cnki.bingduxuebao.003975.
• [54]Ju B,Zhang Q,Ge J,Wang R,Sun J,Ge X,Yu J,Shan S,Zhou B,Song S,Tang X,Yu J,Lan J,Yuan J,Wang H,Zhao J,Zhang S,Wang Y,Shi X,Liu L,Zhao J, Wang X, Zhang Z, Zhang L. Human neutralizing antibodies elicited by SARS-CoV-2 infection[J]. Nature,2020,584(7819):115-119.
• [55]Andreani J,Le Bideau M,Duflot I,Jardot P,Rolland C,Boxberger M,Wurtz N,Rolain J M,Colson P,La Scola B, Raoult D. In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2shows synergistic effect[J]. Microb Pathog,2020,145:104228.
• [56]Mercatelli D, Giorgi F M. Geographic and genomic distribution of SARS-CoV-2 mutations[J/OL]. Front Microbiol, 2020, 11:1800. DOI:10.3389/fmicb.2020.01800.